General Information
Drug ID
Drug Name
Pitavastatin calcium
147526-32-7; 2C25H23FNO4Ca; AK-50694; Alipza; Bis((3R,5S,6E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate), monocalcium salt; CHEBI:71258; Calcium (3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate; Flovas; IYD54XEG3W; Itavastatin calcium; Livalo; Livazo; NK 104 (acid); NK-104; Nisvastatin; Pitavastatin calcium; Pitavastatin calcium (JAN); Pitavastatin hemicalcium; UNII-IYD54XEG3W
Drug Type
Small molecular drug
Indication Dyslipidaemias [ICD11: 5C8Z] Approved [1]
<iframe style="width: 300px; height: 300px;" frameborder="0" src=""></iframe>
Canonical SMILES
C1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)O)O)O)C4=CC=C(C=<br />C4)F.[Ca+2]
CAS Number
CAS 147526-32-7
Pharmaceutical Properties Molecular Weight 880.999 Topological Polar Surface Area 187
Heavy Atom Count 63 Rotatable Bond Count 14
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 12
PubChem CID
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [3]
NTCP Transporter Info Sodium/taurocholate cotransporting polypeptide Substrate [4]
OAT3 Transporter Info Organic anion transporter 3 Substrate [4]
OATP1A2 Transporter Info Organic anion transporting polypeptide 1A2 Substrate [4]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [5]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [6]
OATP2B1 Transporter Info Organic anion transporting polypeptide 2B1 Substrate [7]
Drug-Transporter Activity Data
Drug-Transporter Activity Data BCRP Transporter Info Km = 5.73 microM Human embryonic kidney cells (HEK293)-BCRP [2]
NTCP Transporter Info Km = 15.1 microM Oocytes-NTCP [4]
OAT3 Transporter Info Km = 3.3 microM Oocytes-OAT3 [4]
OATP1A2 Transporter Info Km = 3.4 microM Oocytes-OATP1A2 [4]
OATP1B1 Transporter Info Km = 3 microM Human embryonic kidney cells (HEK293)-OATP1B1 [6]
OATP1B1 Transporter Info Km = 4.8 microM Human embryonic kidney cells (HEK293)-OATP1B1 [8]
OATP1B1 Transporter Info Km = 3.6 microM Oocytes-OATP1B1 [4]
OATP1B1 Transporter Info Km = 6.7 microM Oocytes-OATP1B1 [5]
OATP1B3 Transporter Info Km = 3.25 microM Human embryonic kidney cells (HEK293)-OATP1B3 [6]
OATP1B3 Transporter Info Km = 3.8 microM Oocytes-OATP1B3 [4]
OATP2B1 Transporter Info Km = 1.17 microM Human embryonic kidney cells (HEK293)-OATP2B1 [7]
1 Pitavastatin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol. 2005 Sep;68(3):800-7.
3 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
4 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
5 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
6 Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 Oct;311(1):139-46.
7 Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006 Jul;34(7):1229-36.
8 The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery. Drug Metab Dispos. 2012 Aug;40(8):1641-8.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.